SCULPSURE

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed with the FDA on 2018-06-19 for SCULPSURE manufactured by Cynosure.

Event Text Entries

[111910503] I had sculpsure (a cynosure procedure) performed almost a year ago and had four big problems with it: it is advertised as "painless and comfortable. " that couldn't be further from the truth. I went through the worst contractions you can imagine when i had my last daughter and it is similar to that. It is pain that is probably a 9 on a scale of 10. During the procedure, i didn't think i could carry on. The only reason i was able to is because there are brief waves of no pain in between the excruciating pain; it left me with permanent scar tissue. Balls of scar tissue under my skin on each thigh where i had the procedure performed; i wasn't told that i would need multiple procedures to see results, but after the fact when i told them about the scar tissue they recommended i do the procedure again; the sculpsure yielded no positive cosmetic results whatsoever.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report NumberMW5077949
MDR Report Key7619211
Date Received2018-06-19
Date of Report2018-06-18
Date of Event2017-06-23
Date Added to Maude2018-06-20
Event Key0
Report Source CodeVoluntary report
Manufacturer LinkN
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag0
Reprocessed and Reused Flag3
Reporter OccupationPATIENT
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Single Use3
Previous Use Code3
Event Type3
Type of Report0

Device Details

Brand NameSCULPSURE
Generic NameLASER DISRUPTION OF ADIPOCYTE CELLS
Product CodePKT
Date Received2018-06-19
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by Mfgr*
Device Sequence No1
Device Event Key0
ManufacturerCYNOSURE


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2018-06-19

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.